Key Takeaways
- Broad-based return to growth: All business divisions grew in Q3, with Discovery Services converting China+1 pilots into longer contracts and CDMO biologics gaining momentum, though the demand recovery arrived 8–12 weeks later than expected.
- EBITDA margin jumped 300 bps YoY: Operating EBITDA margin reached 30.1% (vs 27.1% a year ago), helped by a 266 bps improvement in material costs and a swing from forex loss to gain.
- Full-year guide implies a soft 9M: 9M revenue grew only 2% YoY and PAT before exceptionals fell 11.6%, so the single-digit revenue and flat PAT full-year outlook rests on Q4 delivering the recovery that Q3 began.
- US biotech stabilising, finally: Management called the stabilisation "later than expected," and the 8–12 week delay means the second-half recovery thesis only started proving itself in the December quarter.
- What to watch next quarter: Whether the Discovery Services pilot-to-contract conversions actually scale into FY26 revenue, the pace of CDMO biologics order repeat, and any sign that the US biotech stabilisation is durable rather than a single-quarter bounce.
Demand Recovery & Market Dynamics
- Recovery landed late: The demand recovery management had expected in H2 FY25 was delayed by approximately 8–12 weeks, making Q3 the quarter where growth finally showed up rather than Q2.
- US biotech stabilising: Growth in the quarter suggests market dynamics in US biotech are stabilising, though management flagged the stabilisation came "later than expected," implying the sector stayed soft through most of the calendar year.
- China+1 conversion underway: Initial pilot projects with large and midsize pharma companies in Discovery Services started converting into longer-term contracts, a signal that clients are moving from testing Syngene to committing to it as a strategic partner.
- CDMO biologics traction: Repeat orders from existing customers and new collaborations on integrated projects spanning drug development to clinical-stage manufacturing drove positive momentum in the CDMO division.
Hunt: "Growth in the quarter suggests that market dynamics, particularly in US biotech, are stabilising, albeit later than expected."
Divisional Performance
- Discovery Services: The division converted China+1 pilot projects into full-fledged contracts, which are expected to contribute to growth into next year, reflecting increased client confidence in Syngene's science and quality standards.
- CDMO: Led by biologics, the division saw repeat orders and new integrated collaborations covering drug development through clinical-stage manufacturing.
- Research Services: The quarter marked a return to growth in Research Services alongside the CDMO business, with increased traction in biologics.
- All divisions grew: Management stated the quarter saw a return to growth across all business divisions, setting up well for Q4.
Hunt: "Syngene's third quarter performance saw a return to growth across all business divisions that sets us up well for the next quarter."
Margins & Cost Structure
- EBITDA margin expansion: Operating EBITDA margin rose to 30.1% from 27.1% YoY, a 300 bps improvement, supported by ongoing investment in digital initiatives, new technologies and commercial capabilities.
- Material costs the big lever: Material costs improved 266 bps to 25.2% of revenue, staying flat in absolute terms at 237.4 crore despite revenue growth.
- Staff and other costs rose: Staff costs increased 13.7% YoY to 276.1 crore (82 bps higher as a percentage of revenue), and other expenses rose 18.2% YoY to 123 crore (84 bps higher), partly offsetting the material-cost gain.
- Forex swing helped: Foreign exchange swung from a loss of 12.4 crore in the prior-year quarter to a gain of 1.7 crore, providing a tailwind at the operating level.
- 9M margin still down: For the nine months, EBITDA margin declined 52 bps to 26.6%, and PAT before exceptional items fell 11.6% to 291.7 crore, underscoring that Q3's improvement is repairing earlier softness rather than building on a strong base.
Jain: "Reported profit after tax (before exceptional items) for the quarter grew by 14% supported by operating EBITDA margins that came in at 30.1%, up from 27.1% in the previous year."
Exceptional Items & Accounting Changes
- Insurance settlement closed: The 9M FY25 exceptional item of 21.2 crore (net of tax) relates to the final settlement of an insurance claim for loss of fixed assets from a fire incident on 12 December 2016, closing a nearly eight-year-old matter.
- Asset useful life revision: Effective 1 April 2024, Syngene revised the estimated useful life of manufacturing assets (Plant and Machinery and Equipment), which decreased depreciation by ₹5.1 crore for Q1 FY25.
- Tax scheme settlement: The company opted for the Vivad se Vishwas Scheme, 2024, settling pending TDS assessments related to non-resident tax deductions, with a tax expense of ₹9.5 crore disclosed under the scheme.
- Interest on tax refund: Q3 recorded interest income of ₹2.4 crore on an income tax refund for FY 2020-21, booked under Other Income.
Operational Milestones
- 5S certification first: Syngene became the first company in the Indian pharma and life sciences industry to earn the 5S certification for its biologics quality control laboratory, awarded through a joint evaluation by the Union of Japanese Scientists and Engineers (JUSE) and the Quality Circle Forum of India (QCFI).
- Business development focus: Management's stated focus areas are further business development and building the sales pipeline, suggesting the recovery is still in an early, pipeline-filling phase.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Full-year revenue growth | Single-digit growth | FY25 close |
| Full-year PAT | Flat PAT | FY25 close |
| EBITDA guidance | Unchanged from prior guidance | FY25 |
| Q4 momentum | Growth momentum to continue | Q4 FY25 |
| Discovery Services contract contribution | Pilot-to-contract conversions to contribute to growth | Into next year (FY26) |
Key Metrics
| Metric | Q3 FY25 |
|---|---|
| Revenue from operations | ₹944 crores, +11% YoY and +6% QoQ |
| Reported revenue | ₹962 crores, +9% YoY |
| EBITDA from operations | ₹284 crores, +22.5% YoY |
| EBITDA from operations margin | 30.1%, up 293 bps YoY from 27.1% |
| Reported EBITDA | ₹302 crores, +16% YoY |
| Reported EBITDA margin | 31.4%, up from 29.5% YoY |
| PAT before exceptional items | ₹131 crores, +14% YoY |
| PAT margin (before exceptional items) | 13.6%, up 65 bps YoY from 13.0% |
| PAT after exceptional items | ₹131 crores, +18% YoY |
| Full-year revenue growth guidance | Single-digit growth, EBITDA guidance unchanged |
| Full-year PAT guidance | Flat, versus prior year |
| Staff costs as % of revenue from operations | 29.3%, up 82 bps YoY from 28.4% |
| Material costs as % of revenue from operations | 25.2%, improved 266 bps YoY from 27.8% |
| Foreign exchange gain, net | ₹1.7 crore gain, versus ₹12.4 crore loss in Q3 FY24 |
| Cash and cash equivalents | ₹183 crore, versus ₹85.7 crore as of March 2024 |